# B Cell Induction in Pediatric Lung Transplantation

> **NCT02266888** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 45 (actual)

## Conditions studied

- Lung Transplant

## Interventions

- **BIOLOGICAL:** Rituximab (Rituxan®)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02266888
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-22
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-06-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02266888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02266888, "B Cell Induction in Pediatric Lung Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02266888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*